Aldeyra Therapeutics Inc. (ALDX): Price-to-Revenue Ratio

Brandmark of Aldeyra Therapeutics (ALDX)

Aldeyra Therapeutics (ALDX) relies on a virtual model with full outsourcing of development and synthesis. The company's advantage is its non-hormonal platform for combating dry eye. Active engagement with the FDA regarding the launch of reproxal serves as the key driver. The price-to-sales valuation on the GURU.Markets terminal linear chart captures the price action, where the mark reflects the latest data.

ALDX (Aldeyra Therapeutics) P/S Multiple history from 07/04/2022 to 11/14/2026

Metric breakdowns and analytics for Aldeyra Therapeutics Inc. (ALDX)

- stock value and consensus price forecast:
Stock Price Aldeyra Therapeutics Inc.|ALDX - Price Target Chart
- stock exchange capitalization data:
Market Value Aldeyra Therapeutics, Inc.|ALDX - Enterprise Value
- issuer book value statistics:
Equity per Share Aldeyra Therapeutics|ALDX - Book Capitalization|Market-to-Book Ratio aldeyra.com|ALDX - Cumulative Company Assets
- debt obligations and liquidity statistics:
Debt to Capital Aldeyra Therapeutics|ALDX - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Aldeyra Therapeutics, Inc.|ALDX - Company Aggregate Debts|Debts to Book Capitalization Aldeyra Therapeutics, Inc.|ALDX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Aldeyra Therapeutics|Intermediate Liquidity Ratio aldeyra.com
- net income and valuation multiples indicators:
ALDX - Net Profit|Expected Net Income Aldeyra Therapeutics|ALDX - P/E Multiple|Projected Price to Earnings Ratio Aldeyra Therapeutics Inc.|ALDX - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Aldeyra Therapeutics, Inc.|ALDX - Operating profit EBITDA|Net earnings per share (EPS TTM) Aldeyra Therapeutics|ALDX - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months aldeyra.com|ALDX - Earnings growth in current year|Expected net earnings per share growth next year Aldeyra Therapeutics
- issuer revenue and sales details:
ALDX - Company Sales|Projected Sales Volume Aldeyra|ALDX - Market Cap to Revenue|Price to Expected Revenue Ratio Aldeyra Therapeutics, Inc.
General company analysis:ALDX aldeyra.com
Mass-produced product of Aldeyra Therapeutics, Inc.

For the biopharmaceutical sector of Aldeyra Therapeutics (ALDX), the market capitalization-to-revenue ratio reflects market expectations regarding the commercialization of reproxalap and future royalties. An analysis of the median P/S allows for a comparison of the current business value against actual sales volume, determining the degree of optimism priced in ahead of FDA approval and assessing the asset's investment attractiveness through the lens of the multiple.

Who Aldeyra Therapeutics competes with

Price-to-Revenue Ratio ALC (Alcon)|P/S Multiple BLCO (Bausch & Lomb)|Glaukos Corp. - Price-to-Revenue Ratio|Apellis Pharmaceuticals, Inc. - P/S Multiple|BLTE: Price-to-Revenue Ratio|Ocular Therapeutix, Inc. (OCUL) - Price-to-Revenue Ratio|Harrow Inc - Market Capitalization-to-Revenue Ratio|VRDN (Viridian Therapeutics) - P/S Multiple|LENZ: Market Capitalization-to-Revenue Ratio|P/S Multiple OCS|Price-to-Revenue Coefficient eyepointpharma.com|Price-to-Revenue Ratio Kodiak Sciences Inc KOD|Price-to-Revenue Coefficient KALA BIO, Inc. (KALA)|Opus Bio - P/S Multiple|OKYO - P/S Multiple|ADVM: P/S Multiple|OTLK: Market Cap to Sales Volume|Market Cap to Revenue CLSD|P/S Multiple novabay.com|Price-to-Revenue Ratio Kiora Pharmaceuticals Inc. (KPRX)|Price-to-Revenue Coefficient Alimera Sciences, Inc.|P/S Multiple EYEN (Eyenovia, Inc.)|P/S Multiple guardionhealth.com GHSI|OCUP - Price-to-Revenue Ratio|OPT (Opthea Ltd) - Market Cap to Revenue Ratio